ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Séverine Vermeire, Bruce E. Sands, Herbert Tilg, Zsolt Tulassay, Radosław Kempiński, Silvio Danese, Ivan Bunganič, Josianne Nitcheu, Julien Santo, Didier Scherrer, Sophie Biguenet, Hartmut J. Ehrlich, Jean-Marc Steens, Paul Gineste, William J. Sandborn